The European Commission (EC) has granted a line extension in the European Union for Omlyclo (omalizumab), Europe’s first and only omalizumab biosimilar. The EC approved Omlyclo 300mg/2ml prefilled syringe, following approval for 75mg/0.5ml and 150mg/1ml solutions in May 2024. Omlyclo is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!